Abstract
To assess the effects of chemoimmunotherapy on post-chemotherapy cognitive impairments (PCCI) in patients with B-cell non-Hodgkin lymphoma (NHL), we used objective and subjective measures of cognitive functions in combination with serum parameters and neuroelectric recordings. Self-perceived status of cognition, fatigue and emotional functioning were reduced in patients (n=30) compared to healthy controls (n=10). Cognitive performance was impaired in patients with NHL compared to controls and a norm sample (n=1179). PCCI was more severe in patients treated with rituximab and bendamustine (BR) than in patients who received R in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) polychemotherapy (R-CHOP). Individual alpha peak frequency and serum brain-derived neurotrophic factor (BDNF) levels in patients with NHL correlated with accuracy in the objective cognition test. Higher serum interleukin-6 (IL-6) concentrations were associated with higher fatigue levels. Patients with NHL and especially those who were treated with BR were affected by PCCI. BDNF and IL-6 might be involved in the pathogenesis of PCCI and fatigue.
Keywords:
Chemobrain; EEG; cognition; cytokines; fatigue; lymphoma.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
B-Lymphocytes / drug effects*
-
B-Lymphocytes / pathology
-
Bendamustine Hydrochloride / administration & dosage
-
Bendamustine Hydrochloride / adverse effects
-
Brain-Derived Neurotrophic Factor / blood
-
Cognition Disorders / chemically induced
-
Cognition Disorders / diagnosis*
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Electroencephalography
-
Fatigue / chemically induced
-
Fatigue / diagnosis
-
Female
-
Humans
-
Interleukin-6 / blood
-
Lymphoma, Non-Hodgkin / blood
-
Lymphoma, Non-Hodgkin / drug therapy*
-
Male
-
Middle Aged
-
Outcome Assessment, Health Care / methods
-
Prednisone / administration & dosage
-
Prednisone / adverse effects
-
Rituximab / administration & dosage
-
Rituximab / adverse effects
-
Surveys and Questionnaires
-
Vincristine / administration & dosage
-
Vincristine / adverse effects
Substances
-
Brain-Derived Neurotrophic Factor
-
Interleukin-6
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Bendamustine Hydrochloride
-
Prednisone